Bruchfeld, A
320  Ergebnisse:
Personensuche X
?
 
?
2

Risks and treatment related aspects of COVID-19 infection i..:

Antovic, A ; Bruchfeld, A ; Ekland, J...
Scandinavian Journal of Rheumatology, 0300-9742, 2023, 52:4, s. 418-423.  , 2023
 
?
3

COVID-19-related stigma among infected people in Sweden; ps..:

Reinius, M ; Svedhem, V ; Bruchfeld, J...
https://openaccess.city.ac.uk/id/eprint/30774/1/journal.pone.0287341.pdf.  , 2023
 
?
4

Clinical Standards for Diagnosis, Treatment and Prevention ..:

Visca, D ; Centis, R ; Pontali, E...
Int J Tuberc Lung Dis . 2023 Oct 1;27(10):729-741.  , 2023
 
?
 
?
6

Clinical standards for the management of adverse effects du..:

Singh, K P ; Carvalho, A C C ; Centis, R...
https://research.rug.nl/en/publications/8a59196a-d765-4e59-9c3a-666cd1290bc5.  , 2023
 
?
7

Evidence of cytokine activation in patients with post-acute..:

Fredengren, E ; Mahdi, A ; Fedorowski, A...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10207276/.  , 2023
 
?
9

Clinical standards for the management of adverse effects du..:

Singh, K. P ; Carvalho, A. C. C ; Centis, R...
The International Journal of Tuberculosis and Lung Disease, 1027-3719, 2023, 27:7, s. 506-519.  , 2023
 
?
11

Rifapentine access in Europe: growing concerns over key tub..:

Guglielmetti, L ; Günther, G ; Leu, C...
Eur Respir J. 2022 May 19;59(5):2200388. doi:10.1183/13993003.00388-2022. Print 2022 May..  , 2022
 
?
12

Clinical standards for drug-susceptible pulmonary TB:

Akkerman, O. W ; Duarte, R ; Tiberi, S...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9272737/.  , 2022
 
?
13

Clinical standards for drug-susceptible pulmonary TB:

Akkerman, O W ; Duarte, R ; Tiberi, S...
info:eu-repo/semantics/altIdentifier/pmid/35768923.  , 2022
 
?
15

Clinical standards for drug-susceptible pulmonary TB:

Akkerman, O W ; Duarte, R ; Tiberi, S...
https://archive.lstmed.ac.uk/20792/1/s5-2.pdf.  , 2022
 
1-15